CD24 for Cardiovascular Researchers: A Key Molecule in Cardiac Immunology, Marker of Stem Cells and Target for Drug Development
The study of the membrane protein, CD24, and its emerging role in major disease processes, has made a huge leap forward in the past two decades. It appears to have various key roles in oncogenesis, tumor progression and metastasis, stem cell maintenance and immune modulation. First described in the...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2021-04-01
|
| Series: | Journal of Personalized Medicine |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2075-4426/11/4/260 |
| _version_ | 1797539189771730944 |
|---|---|
| author | Eyal Sagiv Michael A. Portman |
| author_facet | Eyal Sagiv Michael A. Portman |
| author_sort | Eyal Sagiv |
| collection | DOAJ |
| description | The study of the membrane protein, CD24, and its emerging role in major disease processes, has made a huge leap forward in the past two decades. It appears to have various key roles in oncogenesis, tumor progression and metastasis, stem cell maintenance and immune modulation. First described in the 1980s as the homologous human protein to the mouse HSA (Heat Stable Antigen), it was reported as a surface marker in developing hematopoietic cell lines. The later discovery of its overexpression in a large number of human neoplasms, lead cancer researchers to discover its various active roles in critical checkpoints during cancer development and progression. Targeting CD24 in directed drug development showed promising results in cancer treatment. More recently, the chimeric CD24-Fc protein has shown exciting results in clinical trials as a specific modulator of auto-inflammatory syndromes. This report is aimed to summarize the relevant literature on CD24 and tie it together with recent advancements in cardiovascular research. We hypothesize that CD24 is a promising focus of research in the understanding of cardiovascular disease processes and the development of novel biological therapies. |
| first_indexed | 2024-03-10T12:42:41Z |
| format | Article |
| id | doaj.art-8e0f6e49192c41389cf44c0f656a46c1 |
| institution | Directory Open Access Journal |
| issn | 2075-4426 |
| language | English |
| last_indexed | 2024-03-10T12:42:41Z |
| publishDate | 2021-04-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Journal of Personalized Medicine |
| spelling | doaj.art-8e0f6e49192c41389cf44c0f656a46c12023-11-21T13:47:23ZengMDPI AGJournal of Personalized Medicine2075-44262021-04-0111426010.3390/jpm11040260CD24 for Cardiovascular Researchers: A Key Molecule in Cardiac Immunology, Marker of Stem Cells and Target for Drug DevelopmentEyal Sagiv0Michael A. Portman1Division of Pediatric Cardiology, Seattle Children’s Hospital and the University of Washington School of Medicine, Seattle, WA 98105, USADivision of Pediatric Cardiology, Seattle Children’s Hospital and the University of Washington School of Medicine, Seattle, WA 98105, USAThe study of the membrane protein, CD24, and its emerging role in major disease processes, has made a huge leap forward in the past two decades. It appears to have various key roles in oncogenesis, tumor progression and metastasis, stem cell maintenance and immune modulation. First described in the 1980s as the homologous human protein to the mouse HSA (Heat Stable Antigen), it was reported as a surface marker in developing hematopoietic cell lines. The later discovery of its overexpression in a large number of human neoplasms, lead cancer researchers to discover its various active roles in critical checkpoints during cancer development and progression. Targeting CD24 in directed drug development showed promising results in cancer treatment. More recently, the chimeric CD24-Fc protein has shown exciting results in clinical trials as a specific modulator of auto-inflammatory syndromes. This report is aimed to summarize the relevant literature on CD24 and tie it together with recent advancements in cardiovascular research. We hypothesize that CD24 is a promising focus of research in the understanding of cardiovascular disease processes and the development of novel biological therapies.https://www.mdpi.com/2075-4426/11/4/260CD24dilated cardiomyopathyvasculitisimmune modulatormultisystem inflammatory syndrome in children (MIS-C) |
| spellingShingle | Eyal Sagiv Michael A. Portman CD24 for Cardiovascular Researchers: A Key Molecule in Cardiac Immunology, Marker of Stem Cells and Target for Drug Development Journal of Personalized Medicine CD24 dilated cardiomyopathy vasculitis immune modulator multisystem inflammatory syndrome in children (MIS-C) |
| title | CD24 for Cardiovascular Researchers: A Key Molecule in Cardiac Immunology, Marker of Stem Cells and Target for Drug Development |
| title_full | CD24 for Cardiovascular Researchers: A Key Molecule in Cardiac Immunology, Marker of Stem Cells and Target for Drug Development |
| title_fullStr | CD24 for Cardiovascular Researchers: A Key Molecule in Cardiac Immunology, Marker of Stem Cells and Target for Drug Development |
| title_full_unstemmed | CD24 for Cardiovascular Researchers: A Key Molecule in Cardiac Immunology, Marker of Stem Cells and Target for Drug Development |
| title_short | CD24 for Cardiovascular Researchers: A Key Molecule in Cardiac Immunology, Marker of Stem Cells and Target for Drug Development |
| title_sort | cd24 for cardiovascular researchers a key molecule in cardiac immunology marker of stem cells and target for drug development |
| topic | CD24 dilated cardiomyopathy vasculitis immune modulator multisystem inflammatory syndrome in children (MIS-C) |
| url | https://www.mdpi.com/2075-4426/11/4/260 |
| work_keys_str_mv | AT eyalsagiv cd24forcardiovascularresearchersakeymoleculeincardiacimmunologymarkerofstemcellsandtargetfordrugdevelopment AT michaelaportman cd24forcardiovascularresearchersakeymoleculeincardiacimmunologymarkerofstemcellsandtargetfordrugdevelopment |